CYADY — Celyad Oncology SA Share Price
Last trade - 00:00- $16.86m
- $12.17m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 0.06 | ||
| PEG Ratio (f) | 0 | ||
| EPS Growth (f) | 47,079.1% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.72 | ||
| Price to Tang. Book | 3.4 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -439.8% | ||
| Return on Equity | -170.72% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 3.12 | 0.01 | 0.01 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +1851.56 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Directors
- Michel Lussier CHM (52)
- Filippo Petti CEO
- Gaetane Metz COO
- Carri Duncan VPR
- Anne Moore VPR
- Richard Mountfield VPR
- Peter De Waele VRD (56)
- Georges Rawadi VBD
- Seron Aymeric OTH
- Philippe Dechamps OTH
- Roland Gordon-Beresford OTH
- Jaak Minten OTH
- Charles Morris OTH
- Anne Portzenheim OTH
- Stephen Rubino OTH (62)
- Margo Roberts DRC (66)
- Marina Udier-Blagovic DRC
- Serge Goblet NED
- Hanspeter Spek NED (67)
- William Wijns NED
- Chris Buyse IND (55)
- Rudy Dekeyser IND
- Jean-Marc Heynderickx IND
- Maria Koehler IND (64)
- Dominic Piscitelli IND (47)
- Louise Proulx IND
- Last Annual
- December 31st, 2022
- Last Interim
- December 31st, 2022
- Incorporated
- July 24th, 2007
- Public Since
- July 5th, 2013
- No. of Employees
- 28
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 22,593,956
- Address
- Axis Business Park Rue Edouard Belin 2, MONT-SAINT-GUIBERT, 1435
- Web
- https://www.celyad.com/
- Phone
- +32 10394100
- Auditors
- Ernst & Young Bedrijfsrevisoren BCV
Similar to CYADY
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Advantis
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 01:05 UTC, shares in Celyad Oncology SA are trading at $0.47. This share price information is delayed by 15 minutes.
Shares in Celyad Oncology SA last closed at $0.47 and the price had moved by -73.14% over the past 365 days. In terms of relative price strength the Celyad Oncology SA share price has underperformed the S&P500 Index by -76.49% over the past year.
The overall consensus recommendation for Celyad Oncology SA is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCelyad Oncology SA does not currently pay a dividend.
Celyad Oncology SA does not currently pay a dividend.
Celyad Oncology SA does not currently pay a dividend.
To buy shares in Celyad Oncology SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.47, shares in Celyad Oncology SA had a market capitalisation of $12.77m.
Here are the trading details for Celyad Oncology SA:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CYADY
Based on an overall assessment of its quality, value and momentum Celyad Oncology SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Celyad Oncology SA is $0.41. That is 11.76% below the last closing price of $0.47.
Analysts covering Celyad Oncology SA currently have a consensus Earnings Per Share (EPS) forecast of €0.64 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Celyad Oncology SA. Over the past six months, its share price has underperformed the S&P500 Index by -72.13%.
As of the last closing price of $0.47, shares in Celyad Oncology SA were trading -47.34% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Celyad Oncology SA PE ratio based on its reported earnings over the past 12 months is 0.06. The shares last closed at $0.47.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Celyad Oncology SA's management team is headed by:
- Michel Lussier - CHM
- Filippo Petti - CEO
- Gaetane Metz - COO
- Carri Duncan - VPR
- Anne Moore - VPR
- Richard Mountfield - VPR
- Peter De Waele - VRD
- Georges Rawadi - VBD
- Seron Aymeric - OTH
- Philippe Dechamps - OTH
- Roland Gordon-Beresford - OTH
- Jaak Minten - OTH
- Charles Morris - OTH
- Anne Portzenheim - OTH
- Stephen Rubino - OTH
- Margo Roberts - DRC
- Marina Udier-Blagovic - DRC
- Serge Goblet - NED
- Hanspeter Spek - NED
- William Wijns - NED
- Chris Buyse - IND
- Rudy Dekeyser - IND
- Jean-Marc Heynderickx - IND
- Maria Koehler - IND
- Dominic Piscitelli - IND
- Louise Proulx - IND